BXRX - Baudax Bio stock surges ~40% as neuromuscular blocker BX1000 shows promise in trial

2023-04-25 08:48:12 ET

• Baudax Bio ( NASDAQ: BXRX ) stock rose ~44% premarket Tuesday after the company reported data from a phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
• BX1000 met the main goal of readiness for intubation (evaluated as Good or Excellent) at all dose levels evaluated ?t at 60 seconds. No severe adverse events were seen in any dose regimen, the company added.
• The trial is is evaluating three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in 80 adult patients undergoing elective surgery using total intravenous anesthesia.
• Baudax noted that the the degree of blockade for the highest dose group appears comparable to that of the standard dose of rocuronium (0.6 mg/kg).
• "We believe these results demonstrate that BX1000 at the highest dose compares favorably to rocuronium, and when combined with our reversal agent BX3000, may provide improved control of neuromuscular paralysis for surgical patients," said Baudax President and CEO Gerri Henwood.
• Neuromuscular blocking agents are usually given during anesthesia to help with endotracheal intubation and improve surgical conditions.
• BXRX +43.62% to $2.70 premarket April 25

For further details see: